background: Recurrent fetal loss (RFL) is a prevalent problem affecting 1% of all women of childbearing age. Many factors can lead to RFL; however, recent studies have indicated the important role of the maternal immune system in this process. The human leukocyte antigens (HLA), HLA-linked genes and regulatory factors play an important role in fetal loss and in fetal development. The current retrospective study was preformed to examine the HLA alleles shared between couples with RFL in Saudi Arabia, using a large cohort of women (having three or more RFL). Specific HLA alleles that could influence this condition, or the number of miscarriages experienced, were expected to be highlighted in this way. conclusions: Although the results of this study suggest that HLA sharing is not an indicative factor in RFL, definitive conclusions on this topic must be based on large case-control studies.
Introduction
Spontaneous miscarriage affects 50% of all pregnancies and is the most common gestational disorder (Wilcox et al., 1988; Brown, 2008) . These miscarriages are either sporadic or recurrent and can be due to chromosome abnormalities and various gene polymorphisms and mutations. Recurrent fetal loss (RFL) remains an enigmatic problem. The prevalence range is 0.8 -2.3% (Alberman, 1988) among all women of reproductive age. This range may be wider if earlier miscarriages ( 4-5 weeks) were detected using the now sensitive HCG testing. Recent epidemiological work has focused on gene polymorphisms and mutations in the autoimmune system and genes within the major histocompatibility complex. Mutations of such genes caused the release of cytokines and natural killer cells, leading to fetal demise and rejection (Choudhury and Knapp, 2001; Costeas et al., 2004; Hunt et al., 2005; Yamada et al., 2005; Wang et al., 2006) .
Inherited thrombophilia, such as factor V Leiden, has also been linked to RFL (Coulam, 1986; Kupferminc et al., 2002; Rey et al., 2003) , though the percentage of Saudi patients with this mutation is very low in comparison to the rest of the Arab world (Almawi et al., 2005 and unpublished data) . In addition, there is an apparent wide variety of gene polymorphisms dependent on ethnicity. However, although some causes are well documented, over 50% of all spontaneous recurrent miscarriages remain idiopathic, i.e. with no known detectable causing factor, and therefore cannot be explained (Christiansen et al., 1989; Stirrat, 1990) .
In recent years, genetic predisposition was proposed as the hidden cause of fetal losses in early and late pregnancies beyond 20 weeks of gestation. The role of human leukocyte antigen (HLA) complexes in this remains controversial due to a lack of firm evidence, as it is unclear whether it is these genes themselves or other linked genes that are the cause (Ober, 1999; Komlos et al., 2007) . However, recently the link between HLA and Killer Ig Receptor genes was proposed as having a possible immunological role in a number of diseases including pre-eclampsia (Rajagopalan and Long, 2005; Zhang et al., 2008) . A clear role of these genes in RFL remains to be elucidated.
In Saudi Arabia, this problem has not been addressed in detail so far. The social infrastructure of the Saudi society remains tribal. A substantial number of marriages are intra-familial and/or intra-tribal. Such a marital structure may well enhance genetic predisposition. The paternal contribution to recurrent pregnancy loss is not clear, however, this contribution has been linked to HLA sharing, as well as chromosomal and possible spermatic anomalies (Ober et al., 1998; Carrell et al., 2003) . As many patient couples are either related or share the same tribe, the number of shared alleles could be expected to be higher (i.e. allele diversity is lower) than seen in other countries. Because of this, any possible association between HLA sharing and RFL is expected to be more prominent within this community. This study aimed to assess the link between HLA sharing and the experience of RFL, as well as the number of RFL experienced.
Materials and Methods

Study design
The RFL Clinic was established in 1994 by one of the investigators (S.M.) in King AbdulAziz Medical City, National Guard Hospital, Riyadh, for treating RFL couples. Patients in this study were from satellite clinics within the National Guard Health Affairs, Riyadh, and from tertiary clinics within the hospital. Informed consent was obtained from both the husband and the wife before beginning investigations. A comprehensive list of investigations, listed below, was given to the couples to be completed within 6 weeks of the first visit, and before any treatment. These investigations included a wide range of tests commonly used for RFL (for more details, see below). Patient samples and those of their husbands were also sent for HLA typing for the Class I antigens HLA-A, HLA-B and HLA-C, and the Class II antigens HLA-DR and HLA-DQ. In addition, a detailed data collection form was filled out for each patient addressing the patient's medical history, including previous obstetric or gynaecological surgeries, and family history. Stage of fetal loss was recorded and categorized as either first trimester (FTM, ≤12 weeks) or second trimester (STM, 12 -22 weeks). The couples were subsequently counselled and a plan of management was prepared for each patient. This study is a retrospective review of these charts for all eligible RFL patients.
Inclusion criteria
Any RFL patient with three or more miscarriages, whose results for all the investigations listed below were within the normal range and, thus, their RFL not explained by any of the examinations performed, was included. From this group, any patient and their partner with normal karyotype, and patients who did not carry the prothrombotic mutations, were included.
Exclusion criteria
Patients with two or less recurrent miscarriages, or patients with three or more RFL and testing positive for any of the investigations that could explain their condition, were excluded. Patients with confirmed antiphospholipid syndrome, Protein S Deficiency or thrombophilia were excluded. Any couple with at least one aborted foetus showing chromosomal anomalies was also excluded from this study.
Data for a total of 383 patients who had experienced RFL, defined here as three or more miscarriages, were collected for this study. Complete investigations and HLA data were available for 253 of the couples. (The majority of the remaining 130 couples did not submit samples for HLA typing, however, in many cases this was due to the patient's husband not wishing to perform the test.) The majority of the mothers were in the age range of 20 -30 years (65%), reflecting the young age of marriage among this community. Within the population of RFL patients in this study, the majority of fetal losses occurred in the FTM (161 couples, 63.6%). STM losses were less prevalent, and 79 (31.2%) of the patients had both FTM and STM losses. Eligible couples were divided into three groups: consanguineous couples [representing the 54 intra-familial couples (21.3%) who were first cousins], non-consanguineous couples [for the 132 couples (52.2%) who were not related to each other] and all couples in this study (total of 253, including 67 couples who only shared their tribal origin).
Investigations
Clinical examination of patients included a full physical examination (general and full pelvic examination). The latter was made with the intention of detecting any anatomical abnormality of the cervix and/or uterus. Details of menstrual cycle and family history for congenital anomalies, diabetes mellitus, heart disease, thyroid disease or deep vein thrombosis were collected. Blood pressure and weight were also measured in the clinic to address hypertension and obesity.
General investigations included testing for infections of Chlamydia, hepatitis, listeria and brucella. Blood work included haemoglobin, white blood and platelet counts and testing for sickle cell anaemia. Fasting blood sugar and 2 h post-glucose measurements were also taken. Hormonal investigations included those for antiphospholipid antibodies, anticardiolipin antibodies, lupus anticoagulant, follicle-stimulating hormone, luteinizing hormone, thyroid-stimulating hormone, prolactin and thyroid antibodies, to ensure all were within normal range. The prothrombotic factors, factor V Leiden and factor II G20 210A mutations, were also studied. When available, aborted fetuses were also sent for karyotyping.
HLA typing
HLA alleles were characterized in all couples visiting the RFL clinic. The enzyme linked probe hybridization assay, from Biotest Diagnostics Corporation, was used as per the manufacturer's instructions. Briefly, sequence-specific oligonucleotide probes were used to detect polymorphic sequence motifs by the ELISA technique. Typing for the Class I antigens HLA-A, HLA-B and HLA-C, and the Class II antigens HLA-DR and HLA-DQ, were done at the King AbdulAziz Medical City hospital's Immunology Laboratory. The HLA typing results for each patient and their partner were then compared to identify the specific alleles shared by the couples. Couples were considered to share a single HLA allele if they both carried the same specific allele. Note that the broad antigens HLA-BW4, -BW6, -DR51, -DR52 and -DR53 were excluded when calculating HLA sharing.
Statistic analysis
Data were entered into a Microsoft Access Database specifically structured for this study. Data were then transferred into the Statistical Package for Social Sciences version 16, which was used for data cleaning, management and analyses. Descriptive analyses were carried out by calculating the number and percent for the categorical variables, whereas the mean was calculated for the continuous variables. Inferential analyses were carried out by calculating the P-value using the ANOVA test. A P-value ≤ 0.05 was considered statistically significant. No correction was performed for the multiple statistical testing using the Bonferroni method.
Results
No relation between RFL and HLA alleles shared between couples
Patients and their partners were HLA typed and the number of shared alleles was calculated. Table I summarizes the number of shared HLA alleles in the five HLA loci studied among all the RFL couples (A), and among the consanguineous (B) and non-consanguineous (C) couples. The most commonly shared alleles/broad antigens in this population were: DQ2, CW7, A*2, DQ6, CW6, B51, DR7 and B50 (in 70, 61, 53, 45, 38, 35, 32 and 26 couples, respectively, data not shown).
The number of RFL couples sharing two HLA alleles was less than those sharing one or no alleles (Table I A and C), except in the case of consanguineous couples (Table I B) , where most of the couples shared two HLA-B and/or -DR alleles. However, the average number of RFL experienced by all three groups of couples remained similar, despite the number or the specific HLA allele shared. In addition, statistical comparison between the mean number of RFL, within each of the three categories, for 0, 1 or 2 shared HLA alleles were not statistically significantly different (Table I) . Only 30 couples (11.9%) shared alleles across all five HLA loci, however, 23 couples (9.1%) did not share any.
The shared HLA alleles in those couples experiencing the highest number of RFL was then examined to elucidate if there is any clear association. One non-consanguineous couple had 27 RFL, the highest number of RFL within this study, yet did not share any of their HLA alleles (data not shown). A consanguineous couple with 13 RFL also did not share any HLA alleles. A further three couples, each experiencing eight RFL, also did not share alleles. Conversely, one consanguineous couple with four RFL shared six alleles (HLA-A*2, -B51, -CW7, -DR13, -DR15 and -DQ6) across the five HLA loci studied.
Limited association between shared HLA loci and stage of RFL
The association between sharing of specific HLA alleles and the stage of RFL, i.e. whether the loss was in the FTM (≤12 weeks) or STM (12 -22 weeks), was examined. Among consanguineous couples an association between FTM losses and sharing of the HLA-B alleles was highlighted (Table I B ). The mean number of FTM losses in couples sharing HLA-B alleles was significantly decreased (P-value ¼ 0.05) compared to those not sharing, although the number of couples in this latter group was small. Even though most of the RFL couples in this study had experienced FTM losses, no other significant differences between the number of shared alleles and FTM losses were seen.
The number of STM losses experienced among all three groups of couples was much less prevalent than FTM losses. However, STM losses experienced by consanguineous couples was significantly increased among those sharing the HLA-B alleles compared to those who did not share this locus (P-value ¼ 0.03, Table I B) . Among non-consanguineous couples, only increased sharing of HLA-C alleles showed a significant increase in STM losses experienced (P-value ¼ 0.04, Table I C), although the number of couples sharing this locus was small. No further change in the mean number of STM and sharing of HLA alleles was observed among any of the groups. It is worth noting that in the 30 patients sharing across the five HLA loci, the number of FTM and STM losses was just below and above the average, respectively, when compared with those for single locus sharing (data not shown).
Discussion
In this study, we aimed to examine the extent of HLA sharing between RFL patients and their partners, and to elucidate if it could be linked with their condition. Upon examination of our data, we could find no obvious relationship between the specific HLA alleles shared, or the number shared across the loci typed, and a couple's RFL or the number of RFL experienced. It has previously been suggested that increased risk of RFL is associated with couples sharing specific HLA alleles and their extended HLA haplotype (Ober et al., 1992; Kruse et al., 2004; Shankarkumar et al., 2008) . Owing to the high consanguinity of the Saudi Arabian population, and therefore the likelihood of HLA sharing between the couples being high, this hypothesis was tested here. In this way, we also sought to address if HLA sharing between RFL couples is a useful tool for diagnosis and/or the management of treatment for RFL.
In this study, 253 patients, with three or more RFL, and their partners were typed for the Class I HLA-A, -B and -C antigens, as well as the Class II HLA-DR and -DQ antigens. It was expected that any HLA allele/locus that is most commonly associated with RFL would be seen in those couples with the largest number of RFL. Contrary to previous reports, we did not find that an increase of sharing in any of the HLA alleles typed was related to the mean number of RFL experienced. Among these patients, 23 did not share any of their HLA alleles. These included couples suffering from the lowest number of three RFLs, to the highest number of 27 RFLs. Conversely, 30 couples sharing all five HLA loci studied (at five or more alleles) also had a wide range in the number of RFL experienced (three to nine); sharing of six alleles in all five HLA loci typed was seen for one couple with four RFL. In addition, one couple with 19 RFL shared three HLA alleles (HLA-CW7, -DR17 and -DQ2) and, furthermore, five couples with 10 -13 RFL shared between one and three HLA alleles (none of these alleles were in common with each other). In Table I B and C, a few statistical significant differences were seen. However, it should be noted that these were probably due to small patient numbers and multiple testing, and therefore would not be seen as significant differences after Bonferroni correction. These results would therefore suggest that there is no clear relationship between the HLA alleles shared between couples, their relationship to each other and the number of RFL experienced.
Due to the social structure in Saudi Arabia, patients with normal pregnancies visiting the hospital would not normally consent to HLA typing. We were therefore unable to compare RFL patients from this study with the wider Saudi population of normal fecundity in order to identify if particular HLA alleles were more frequently associated with RFL. Without suitable controls our conclusions are subjective, however, the allelic frequencies we have observed were not expected. Many studies have been done to definitively address HLA sharing. Varla-Leftherioti et al. (2007 , 2010 found that the degree of sharing of HLA alleles among RFL couples did not differ from control couples in either the total number or in the HLA-DQA1*0505 allele studied. Other authors have highlighted higher allelic frequencies for HLA-B, HLA-DR and HLA-DQ alleles among RFL patients than those seen in the normal healthy population (Ober et al., 1992; . Comparison of HLA between the couples is represented as no sharing (0), sharing one allele (1) or sharing two alleles (2). Sharing is shown in relation to the mean number of RFL (standard deviation in parentheses) and stage of RFL, either first trimester (FTM) or second trimester (STM). Takakuwa et al., 2003; Kruse et al., 2004) . Of comparative interest here are the data derived by studying another intra-related population of the Hutterites, where sharing in HLA-B or across 16-locus haplotype has been associated with decreased fecundability (Ober et al., 1992; Ober, 1999) . These couples, however, do not experience more than two fetal losses. It was expected that a similar result would be found here if HLA-B was directly associated with RFL. Among our population, we found that only consanguineous couples were more likely to experience STM than FTM losses if they shared their HLA-B alleles. However, our findings do not indicate that an increase in HLA sharing of this or any other alleles typed contributes to the number of RFL experienced by the patients studied here. Together these results suggest that HLA sharing per se has no direct relation to RFL, or the number of fetal losses experienced by the patient. Many recent publications have implicated HLA-G polymorphisms to be associated with RFL (Ober et al., 2003; Hviid and Christiansen, 2005; Suryanarayana et al., 2008) . Though this locus was not studied here, it has widely been accepted that HLA-linked genes are probably more directly involved in fetal demise. It may not necessarily be the degree of sharing of HLA alleles that these couple have that relates to their RFL, but more likely the related specific HLAlinked gene or genes. Until those HLA-linked genes have been identified, the results of our paper would conclude that HLA typing for the Class I antigens HLA-A, HLA-B and HLA-C, and Class II antigens HLA-DR and HLA-DQ is not necessarily an informative or effective method for use in RFL diagnosis or management. Instead more focus should to be put on the history of the patient's fetal loss and immunological factors inherent within the couple. Providing counselling for those patients at risk of RFL and management of their condition continues to be the current recommended methods of treatment (Regan et al., 2003) . Future studies will analyse the different management regimens that were used to treat and manage these RFL patients.
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